Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

NCT06173505 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT06173505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06173505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
Lead sponsor
Xencor, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 27, 2023
Completion date
December 29, 2025
Enrollment
28 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

nonsquamous non-small cell lung cancer